Nurulain T. Zaveri

Nurulain T. Zaveri

Auto-generated profile, based on publicly available information

Nurulain T. Zaveri

Astraea Therapeutics, Mountain View, CA, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Neuron
Verified
Journal Article
Closed access
AGAnant Gharpure
Anant Gharpure
JTJinfeng Teng
Jinfeng Teng
YZYuxuan Zhuang
Yuxuan Zhuang
CNColleen M. Noviello
Colleen M. Noviello
RWRichard M. Walsh
Richard M. Walsh
RHRyan E. Hibbs
Ryan E. Hibbs

29 August 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
HDHuiping Ding
Huiping Ding
NKNorikazu Kiguchi
Norikazu Kiguchi
DYDennis Yasuda
Dennis Yasuda
PDPankaj R. Daga
Pankaj R. Daga
WPWillma E. Polgar
Willma E. Polgar
MKMei-Chuan Ko
Mei-Chuan Ko
The small-molecule AT-121 is an agonist of nociceptin and mu opioid peptide receptors and mediates analgesia without opioid-associated side effects in nonhuman primates.


1 December 2009 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
LTLawrence Toll
Lawrence Toll
TKTaline V. Khroyan
Taline V. Khroyan
WPWillma E. Polgar
Willma E. Polgar
FJFaming Jiang
Faming Jiang
COCris Olsen
Cris Olsen
NZNurulain T. Zaveri
Nurulain T. Zaveri
The nociceptin receptor (NOPr), a member of the opioid receptor family, is a target for the treatment of pain and drug abuse. Nociceptin/orphanin FQ (N/OFQ), the endogenous peptide for NOPr, not only modulates opioid antinociception, but also blocks the rewarding effects of several abused drugs, such as morphine, cocaine, and amphetamine. We hypothesized that NOPr agonists, with bifunctional activity at the μ-opioid receptor (MOPr), may function as nonaddicting analgesics or as drug abuse medications. Bifunctional small-molecule NOPr agonists possessing different selectivities and efficacies at MOPr were evaluated in an acute thermal antinociception assay, and for their ability to induce conditioned place preference (CPP) and their effect on morphine-induced CPP. 1-(1-Cyclooctylpiperidin-4-yl)-indolin-2-one) (SR14150), a high-affinity NOPr partial agonist, with low MOPr affinity and efficacy, produced analgesia that was naloxone-reversible. SR14150 did not induce CPP alone, nor did it attenuate morphine-induced CPP. 3-Ethyl-1-(1-(4-isopropylcyclohexyl)piperidin-4-yl)-indolin-2-one (SR16507), which has high affinity for both NOPr and MOPr, full agonist activity at NOPr, and partial agonist activity at MOPr, was also a potent analgesic and produced CPP alone, but also modestly attenuated morphine CPP. 1-(1-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)piperidinl-4-yl)-indolin-2-one (SR16835), a NOPr full agonist and low-affinity MOPr partial agonist, was not antinociceptive, did not produce CPP alone, but attenuated morphine CPP. Our results suggest that NOPr full-agonist activity is required to modulate opioid-induced reward, whereas a bifunctional NOPr/MOPr partial agonist profile may be suitable as a nonaddicting analgesic. The opioid-modulating effects of the NOPr ligands may be used effectively to produce better medications for treatment of drug abuse and pain.

25 January 2012 in Neuropsychopharmacology
Verified
Journal Article
Closed access
LTLawrence Toll
Lawrence Toll
NZNurulain T Zaveri
Nurulain T Zaveri
WPWillma E Polgar
Willma E Polgar
FJFaming Jiang
Faming Jiang
TKTaline V Khroyan
Taline V Khroyan
FLFrances M Leslie
Frances M Leslie

1 May 2011 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
NZNurulain T. Zaveri
Nurulain T. Zaveri
Several studies show that the nociceptin receptor NOP plays a role in the regulation of reward and motivation pathways related to substance abuse. Administration of the NOPs natural peptide ligand, Nociceptin/Orphanin FQ (N/OFQ) or synthetic agonist Ro 64-6198 has been shown to block rewarding effects of cocaine, morphine, amphetamines and alcohol, in various behavioral models of drug reward and reinforcement, such as conditioned place preference and drug self-administration. Administration of N/OFQ has been shown to reduce drug-stimulated levels of dopamine in mesolimbic pathways. The NOP-N/OFQ system has been particularly well examined in the development of alcohol abuse in animal models. Furthermore, the efficacy of the mixed-action opioid buprenorphine, in attenuating alcohol consumption in human addicts and in alcohol-preferring animal models, at higher doses, has been attributed to its partial agonist activity at the NOP receptor. These studies suggest that NOP receptor agonists may have potential as drug abuse medications. However, the pathophysiology of addiction is complex and drug addiction pharmacotherapy needs to address the various phases of substance addiction (craving, withdrawal, relapse). Further studies are needed to clearly establish how NOP agonists may attenuate the drug addiction process and provide therapeutic benefit. Addiction to multiple abused drugs (polydrug addiction) is now commonplace and presents a treatment challenge, given the limited pharmacotherapies currently approved. Polydrug addiction may not be adequately treated by a single agent with a single mechanism of action. As with the case of buprenorphine, a mixed-action profile of NOP/opioid activity may provide a more effective drug to treat addiction to various abused substances and/or polydrug addiction.